Ken Griffin Purple Biotech Ltd. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Purple Biotech Ltd. stock. As of the latest transaction made, Citadel Advisors LLC holds 5,600 shares of PPBT stock, worth $33,040. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,600
Previous 6,600
15.15%
Holding current value
$33,040
Previous $4,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding PPBT
# of Institutions
23Shares Held
1.91MCall Options Held
5.6KPut Options Held
0-
Armistice Capital, LLC New York, NY1.36MShares$8.01 Million0.01% of portfolio
-
Kingswood Wealth Advisors, LLC San Diego, CA208KShares$1.23 Million0.01% of portfolio
-
Morgan Stanley New York, NY203KShares$1.2 Million0.0% of portfolio
-
Venture Visionary Partners LLC22.2KShares$130,7490.0% of portfolio
-
Virtu Financial LLC New York, NY19.3KShares$113,7100.0% of portfolio
About PURPLE BIOTECH LTD.
- Ticker PPBT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,303,300
- Market Cap $108M
- Description
- Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhi...